We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.00 | -6.25% | 45.00 | 44.50 | 45.30 | 46.00 | 44.60 | 44.60 | 71,573 | 15:22:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 169.74M | -23.15M | -0.0313 | -15.34 | 354.89M |
From Apr 2019 to Apr 2024
TIDMBMK
RNS Number : 6166X
Benchmark Holdings PLC
20 December 2019
20 December 2019
Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Full Year Results for the Financial Year Ended 30 September 2019
Challenging market conditions led to disappointing performance
and accelerating the restructuring of the Group
Good progress towards launch of BMK08 and CleanTreat(R) and of SPR Shrimp in Asia
Benchmark, the aquaculture health, nutrition and genetics business, announces its audited full year results for the year ended 30 September 2019 (the "period"). A copy of the Company's Annual Report can be found on https://www.benchmarkplc.com
The Company also announces that Septima Maguire is assuming the role of CFO effective today.
Hot Features
Premium
GBPm Restated* %
2019 2018
-------------------------------------------- -------- ---------- -----
Adjusted
-------------------------------------------- -------- ---------- -----
Adjusted EBITDA(2) from continuing
operations 12.1 19.1 -37%
-------------------------------------------- -------- ---------- -----
Total Adjusted EBITDA(2) - incl.
discontinued operations 13.7 17.0 -19%
-------------------------------------------- -------- ---------- -----
Adjusted Operating Profit(3) from
continuing operations 3.6 14.2 -75%
-------------------------------------------- -------- ---------- -----
Statutory
-------------------------------------------- -------- ---------- -----
Revenue from continuing operations 127.3 131.6 -3%
-------------------------------------------- -------- ---------- -----
Loss before tax from continuing operations (73.3) (8.4)
-------------------------------------------- -------- ---------- -----
Loss/profit for the period from continuing
operations (73.3) 0.5
-------------------------------------------- -------- ---------- -----
Loss for the period - total incl.
discontinued operations (83.1) (4.4)
-------------------------------------------- -------- ---------- -----
Basic loss per share (p) (15.03) (0.94)
-------------------------------------------- -------- ---------- -----
Net debt(4) (87.1) (55.7)
-------------------------------------------- -------- ---------- -----
* 2018 numbers have been restated to reflect the ongoing continuing business. Knowledge Services Division and the veterinary services business within the Animal Health Division have been moved to discontinued operations in line with IFRS 5.
Financial Overview
As announced in the Company's Trading Update of 29 November 2019, the Group has accelerated the disposal and discontinuation of non-core activities. These activities have been excluded from Continuing Operations.
-- Revenues from Continuing Operations of GBP127.3m, 3% below prior year (2018: GBP131.6m)
-- Total revenues including Continuing and Discontinued Operations of GBP148.7m, down 2% (2018: GBP151.5m)
-- Adjusted EBITDA(2) from Continuing Operations of GBP12.1m (2018: GBP19.1m)
-- Total Adjusted EBITDA(2) including Continuing and Discontinued Operations of GBP13.7m (2018: GBP17.0m)
-- Total R&D investment of GBP20.5m (2018: GBP19.2m) driven by products close to launch and investment in Genetics and Advanced Nutrition to maintain leadership in our core markets
-- Net debt(4) at period end of GBP87.1m (2018: GBP55.7m) as a result of investment in R&D and an increase in working capital including that related to growth in biological assets in the new production facilities
-- Year end Liquidity(5) was GBP28.2m, well within the covenant threshold
-- Loss for the period from continuing operations of GBP73.3m driven by an impairment of intangible assets related to INVE of GBP44.8m as a result of a reduction in forecasts in Advanced Nutrition due to material change in market outlook.
Current trading:
-- Weakness in the shrimp and sea bass/bream markets continues and while some recovery is expected it is unlikely to recover to 2018 levels in 2020. The outlook in the salmon market remains positive
-- Overall the Company expects to deliver underlying Adjusted EBITDA from Continuing Operations (before one-off other income) in line with this year in FY2020 and to maintain sufficient liquidity to execute its product development programme and support its Continuing Operations after taking account of the expected timing and proceeds from the planned disposals and cost reductions
(1) EBITDA is earnings before interest, tax, depreciation and amortisation and impairment.
(2) Adjusted EBITDA is EBITDA(1) , before exceptional items and acquisition related expenditure.
(3) Adjusted Operating Profit is operating loss before exceptional items including acquisition related items and amortisation of intangible assets excluding development costs
(4) Net debt is cash and cash equivalents less loans and borrowings.
(5) Liquidity is defined as undrawn facilities plus cash balances.
(6) Constant Currency reflects 2019 figures in GBP converted using average foreign exchange rates prevalent in 2018
Peter George, Executive Chairman commented:
"Following these disappointing results, and the management changes announced in August, our priorities for the coming year are to deliver the programme of disposals and restructuring, to obtain regulatory approval and prepare for launch of BMK08 and CleanTreat(Ò) and to execute our strategy in our core business areas of Genetics and Advanced Nutrition, including the launch of SPR shrimp and the expansion of our health and specialist diets segments in Advanced Nutrition.
"There is a growing need in the market for solutions that improve the sustainability of food production in aquaculture. Benchmark's focus on delivering products and solutions that improve animal health and welfare, and that reduce environmental impact, positions it as a leader in raising the sustainability standards in aquaculture."
Operational Highlights
Progress towards commercial launch of major products
-- Next generation sea lice treatment (product candidate BMK08) continued to show c.99% efficacy and excellent environmental and animal welfare credentials. In combination with CleanTreat(R), BMK08 is potentially transformative, addressing one of the largest industry challenges.
-- Production of specific pathogen resistant (SPR) shrimp commenced in Florida for export into Asia. Establishment of associate in Thailand for local multiplication and distribution.
Growth in core markets
-- Opening of state of the art, land-based salmon egg facility in Norway. Ramp-up of production according to plan
-- Establishment of wholly owned local production in Chile following dissolution of JV with AquaChile. Recovery of original investment which will be reinvested in the Chilean operation
-- Increased capacity at nutrition production plant in Thailand to meet growing long term demand for the Company's specialist diets
Continued Innovation
-- Winner of Aquaculture Innovation Award for CleanTreat(R), the Company's breakthrough purification system which removes medicinal residues from bath treatments
-- Launch of a new Artemia product (D-FENSE) which reduces the risk of infection from vibrio, one of the main industry challenges affecting shrimp and seabass/seabream
Details of analyst / investor call today
There will be a call at 8:30am UK time today for analysts and investors. To register for the call please contact MHP Communications on +44 (0)20 3128 8742, or by email on benchmark@mhpc.com
Enquiries
For further information, please contact: Benchmark Holdings plc Tel: 020 3696 0630 Peter George, Executive Chairman Mark Plampin/Septima Maguire, CFO Ivonne Cantu, Investor Relations Numis (Broker and NOMAD) Tel: 020 7260 1000 James Black, Freddie Barnfield, Duncan Monteith MHP Communications Tel: 020 3128 8742
Katie Hunt, Reg Hoare, Alistair de Kare-Silver benchmark@mphc.com
About Benchmark
Benchmark's mission is to enable food producers to improve their sustainability and profitability.
We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com
Chairman's Statement
Overview
I am disappointed to be reporting results that are below those expected at the beginning of the financial year, due largely to poor market conditions affecting our largest division, Advanced Nutrition.
Following the management changes announced in August, the Company has accelerated its programme of efficiencies including the disposal and exit from non-core businesses and the implementation of a cost saving plan.
Revenues for the year from continuing operations were down 3% at GBP127.3m (2018: GBP131.6m); and Adjusted EBITDA from continuing operations was GBP12.1m (2018: GBP19.1m). Total Adjusted EBITDA (including the results of discontinued operations)(2) was GBP13.7m (2018: GBP17.0m). After tax loss for the year from continuing operations was GBP73.3m (2018: profit of GBP0.5m) mainly driven by an impairment of intangible assets related to INVE of GBP44.8m as a result of a reduction in forecasts in Advanced Nutrition due to material change in market outlook.
During the year the Company made good progress towards the launch of its next generation sea lice treatment, product candidate BMK08, which, together with its co-dependent technology CleanTreat(Ò) , has the potential to be transformational for the industry, delivering a solution with strong environmental and animal welfare credentials. The Company is considering the optimal strategy to scale up CleanTreat(R) given its importance to product candidate BMK08 and its broader industry wide applications.
Challenging markets in Advanced Nutrition
2019 was a challenging year for Advanced Nutrition, our largest division, representing more than 50% of the Group's revenues. Our main customers in shrimp faced declining prices and negative margin development, leading to reduced production, and affecting demand for our products. Industry commentators remark that these were the lowest price levels in the shrimp industry in 30 years (inflation adjusted) resulting from overstocking after a record production in 2018. In Artemia, the division's main product, the situation was exacerbated by strong harvests and increased competition which resulted in price pressure.
The Mediterranean sea bass and sea bream markets were also affected by oversupply after a period of high stocking which affected prices, dropping to levels not seen since 2012. In Turkey, the largest producing country, this was exacerbated by the adverse economic environment, including high inflation and limited access to credit. Overall, producers reacted by contracting production reducing demand for our products.
As a result, revenues in Advanced Nutrition were down 10% to GBP76.8m (2018: GBP85.7m) and revenues from Artemia (in USD) were down by 23%. The division's specialist diets and health were more resilient to market conditions with sales down by c.5%. Margins in the division were lower than the previous year reflecting the fall in revenues.
Advanced Nutrition is a core business for the Company with leading positions in its markets and opportunities for growth. The Company increased its market share in health and specialist diets in the year and we continue to see an opportunity to expand into the grow-out segment with these products building a new sales channel. However, market conditions are expected to remain difficult during 2020 and as a consequence of the impact of weak markets on trading and constraints on cash investment, the carrying value of the intangible assets related to the acquisition of INVE has been impaired by GBP44.8m.
Good performance in Genetics and progress towards launch of disease resistant shrimp
Genetics, our second largest division, continued to perform well, delivering growth in revenues and Adjusted EBITDA. Genetics revenues of GBP39.7m were up 11%, ahead of the reported growth in the global salmon farming sector of 6%. Growth in revenues was driven by an increase in salmon egg sales, and pricing that reflects our continued innovation. Looking forward, the Company's increased capacity, following the opening of the new land-based facility in Norway, and its ongoing innovation programme to introduce new genetic traits, will support future growth.
During the year, we announced the dissolution of the Company's joint venture with AquaChile as a result of AquaChile's acquisition by AgroSuper. We continue to believe that Chile is a strategically important market for our business and our focus during the dissolution process was on recovering our original investment in the JV and on finding an alternative route to establish local production of salmon eggs, in line with our original objective. The dissolution of the JV was successfully completed in FY2019 and the balance of the consideration due was received post year end. The ownership of the Ensenada salmon egg hatchery facility to Benchmark will form the platform for the Group to establish local production. We will reinvest the amount repaid to convert the Ensenada hatchery facility into a full salmon egg production operation over the next 18 months.
The Company made progress towards the launch of its specific pathogen resistant (SPR) shrimp genetics business in Asia which represents a significant growth opportunity for the Company, leveraging its strong market position in shrimp. During the year, the Company commenced production of its SPR shrimp in Florida for export to Asian markets. In addition, the Company entered into an agreement with two partners in Thailand for local multiplication and distribution of our shrimp genetics products. The establishment of the agreement is in line with our strategy to use local partners to accelerate market entry while reducing capital commitments and mitigating risk. We see a very significant opportunity to introduce advanced genetics which improve performance and disease resistance in the shrimp sector, and our competitive genetics and market presence position us strongly to succeed.
Animal Health
Progress towards launch of BMK08
I am pleased with the progress made towards the launch of BMK08 supported by our proprietary water purification system, CleanTreatÒ. During the year the Company conducted additional large-scale trials with new customers which continued to show high levels of efficacy and excellent animal welfare and environmental credentials. The Group is preparing for commercial launch in Q1 2021CY, however regulatory timings are not within the Group's control.
There is increasing recognition in the industry of the breakthrough nature of our sea lice treatment and increasing interest from customers as we approach commercial launch. Sea lice continues to represent the industry's most important biological challenge, resulting in production losses and reputational impact; the market for the treatment and prevention of sea lice is estimated to be GBP2-GBP3bn.
Innovation award for CleanTreat(Ò)
CleanTreat(Ò) , the Company's proprietary system that removes medicinal residues from treatment water, and which is integral to the delivery of BMK08, was awarded a prestigious industry innovation award at the world's largest aquaculture technology exhibition, AquaNor. CleanTreat(Ò) addresses one of the biggest concerns in the salmon industry regarding the environmental impact of bath treatments. CleanTreat(Ò) has broad potential applications in the aquaculture industry beyond sea lice with the potential to eliminate detectable medicinal residues across bath treatments. The Company is considering the optimal strategy to scale up CleanTreat(R) given its importance to product candidate BMK08 and its broader applications, including alternative funding strategies with support from its major shareholders.
BMK08 in combination with CleanTreat(Ò) is potentially transformative, addressing the urgent need for a highly efficacious treatment that protects the environment and animal welfare.
Streamlining of animal health pipeline and trial facilities
During the year the Company conducted a further review of the health pipeline, led by incoming CSO Alex Raeber, and made the decision to focus efforts on a smaller number of products. We stopped development in projects outside of our core species and in projects that have not passed the proof of concept stage. We also phased out some of our programmes. The Company's main opportunities continue to be product candidate BMK08, and the vaccine portfolios for sea bass/sea bream and salmon. The review extended to the Company's in-house trial facilities and led to the decision to restructure these. The positive impact from this effort will come through from FY2020 onwards.
The Company experienced longer timescales than anticipated in the development of its sea bass/sea bream vaccines, and in establishing the commercial trials of certain pipeline products, which had an impact on Group revenues and on the expected timing of commercial launch of certain products. In addition, it was established that fewer trials of BMK08 were required for its regulatory process than previously anticipated. The Company is adopting a more conservative approach to forecasting development timescales and revenues from new products. It is expected that the first vaccine for the sea bass/sea bream market will be launched in the first half of the calendar year 2020.
Strategy
The Board's annual strategic review with the leadership team took place in September, and focussed on a review of progress against the Company's strategy set out a year ago, including the launch of BMK08 and of SPR shrimp.
Our priorities for the next 12 months are to execute the programme of disposals and restructuring, to obtain regulatory approval and prepare for the commercial launch of BMK08 and CleanTreat(Ò) , and to execute our strategy in our core business areas of Genetics and Advanced Nutrition, including the launch of SPR shrimp in Genetics and the expansion of our health and diets segments in Advanced Nutrition.
Board and management changes
The year was marked by significant changes to the Company's senior management team; the Board believes it is the right time in the Company's development to appoint a new management team with the experience and focus to execute the next phase of Benchmark's strategy, deliver growth and accelerate the path to sustained profitability.
Septima Maguire joined the Company on 11 November 2019. Septima replaces Mark Plampin, who after nine years in the role of CFO, decided to step down to pursue other opportunities. Mark has been an integral part of the team that led the Group through its IPO on AIM and the acquisitive and organic growth that followed. Malcolm Pye announced his intention to step down as CEO and he resigned from the Board post period-end on 4 December 2019. The recruitment of a CEO to succeed Malcolm Pye is underway.
I took over as Executive Chairman in August following Malcolm's decision to step down, and since then my priority has been to accelerate the programme of disposals, drive operational and cost efficiencies and bring a sharper focus on the product pipeline.
Liquidity and cash management
Liquidity and cash management continued to be a priority for the Company throughout the year. This is of critical importance while the Company continues to invest in R&D ahead of the launch of product candidate BMK08 and other pipeline products. At year end, the Company had net debt of GBP87.1m and liquidity(5) (undrawn facilities plus cash balances) of GBP28.2m, significantly above the covenant minimum of GBP10m.
A comprehensive programme to strengthen the Company's balance sheet has been undertaken by the new management, including the disposal of or exit from non-core businesses, a cost reduction/cost containment plan and enhanced working capital management. The timing and proceeds from these actions are fundamental for Benchmark to maintain sufficient liquidity to execute the Group's product development programme and to support its continuing operations.
The disposals primarily relate to businesses in the Knowledge Services division, including veterinary training, publishing, conferences and consultancy services, which are not core to our strategic focus on aquaculture genetics, health and advanced nutrition. The Company has appointed external advisers in order to accelerate the programme of disposals and expects these to conclude in 2020. Discussions with potential partners for the commercialisation of our companion animal products are ongoing.
Going concern
The Board has reviewed the Group's forecast for the period to September 2021 and concluded that, while there is material uncertainty surrounding the timing and value of proceeds from the disposal of discontinued operations and other trading sensitivities, the Group should be able to continue to operate as a going concern subject to successful completion of those disposals or by implementing mitigating actions that significantly reduce the investment and costs related to the product pipeline or by further finance being sought.
Summary and outlook
Weakness in the shrimp and sea bass/bream markets continues and while some recovery is expected they are unlikely to recover to 2018 levels in 2020.
Overall the Company expects to deliver underlying Adjusted EBITDA from continuing operations (before one-off other income) in line with this year in FY2020 and to maintain sufficient liquidity to execute its product development programme and support its continuing operations after taking account of the expected timing and the proceeds from the planned disposals and cost reductions.
The market has a growing need for solutions that improve the sustainability of food production in aquaculture. Benchmark's focus on delivering products and solutions that improve animal health and welfare, and that reduce environmental impact, positions it as a leader in improving sustainability standards in aquaculture.
Financial Review
Revenue and Adjusted EBITDA
Group
The Advanced Nutrition division experienced very challenging market conditions in 2019 that led to a reduction in revenue, which was partially offset by growth in Genetics and as a result Group revenue from continuing operations decreased by 3% to GBP127.3m in the year (2018: GBP131.6m). The reduction in sales meant that Gross Profit from continuing operations decreased to GBP66.0m (2018: GBP68.5m) and Gross Margin remaining stead at 52% (2018: 52%) as prices remained relatively resilient albeit some price weakness was experienced in certain live feed products. In addition, there was a reduced contribution in Health from commercial scale field trials.
Total Group operating costs of continuing operations increased by 10% to GBP40.7m (2018: GBP37.0m). This increase reflects the operating costs of new production sites as they come on stream, increased costs related to currency transfers and a full year impact of increased management headcount to strengthen the Plc and Operations boards. Opex was reduced by other income of GBP1.8m (2018: GBP1.0m), mainly from R&D expenditure credits and proceeds from successful IP infringement cases. Expensed R&D of continuing operations increased to GBP12.8m (2018: GBP12.0m) with the increase being focussed on protecting the market positions of the more mature Genetics and Advanced Nutrition divisions as well as progressing the main pipeline opportunities in Animal Health.
Adjusted EBITDA from continuing operations decreased by 37% to GBP12.1m (2018: GBP19.1m) with the drop driven by lower sales in Advanced Nutrition and lower contribution from commercial scale field trials, offset by an increase in sales and margins in Genetics and one-off other income. Adjusted Operating Profit from continuing operations decreased to GBP3.6m (2018: GBP14.2m) due to the lower trading result combined with increased depreciation charges reflecting the contribution of the recently constructed production assets.
Total revenues (including discontinued operations) were GBP148.7m, down 2% (2018: GBP151.5m). Using the same foreign exchange rates experienced in 2018 (constant currency(6) ) revenue from continuing operations decreased by 3%. Total Adjusted EBITDA (including discontinued operations) decreased by 19% to GBP13.7m (2018: GBP17.0m). Using constant currency total Adjusted EBITDA decreased by 17%.
Advanced Nutrition
Revenue of GBP76.8m down 10% (2018: GBP85.7m) as a result of weak markets and aggressive price competition from CIS Artemia producers after a strong harvest. By product our live feed products were the most affected with volumes and revenues (in USD) down 23%, whilst specialist diets and health showed relative resilience with revenues (in USD) down 5% and 4%, respectively.
Strategically we maintained our prices and our premium positioning, which reflect our technical superiority. The weak demand environment did result in the division absorbing some increases in cost of sales and, while operating costs were tightly controlled and benefitted from the profit on sale of a property and the proceeds of IP infringement settlements, Advanced Nutrition reported a reduced Adjusted EBITDA result of GBP15.4m (2018: GBP21.6m) with a margin of 20% (2018: 25%). The weaker market outlook has resulted in an impairment of GBP44.8m to the carrying values of goodwill in the INVE business.
Genetics
Good growth in revenue and Adjusted EBITDA driven by an increase in salmon egg volumes (+16%) and prices reflecting our continued innovation and launch of new traits. Revenues of GBP39.7m were up 11% (2018: GBP35.8m), ahead of growth in the sector. The Company's ongoing innovation together with its investment in quality, biosecurity and availability of supply through our new production facilities will support future growth. The dissolution of the joint venture with AquaChile is now complete including transfer of ownership of the Ensenada salmon egg hatchery which will form the platform to establish Chilean production. The valuation of biological assets increased by GBP8.3m (2018: GBP4.0m) driven by the growth in sales in the year, the strong order book at the year end and the increasing output potential of the new production sites. As the division's new shrimp genetics get closer to market launch the costs of development were capitalised for the first time, with GBP1.5m capitalised in the year. These factors supported growth in gross margins to 64% (2018: 58%). Operating costs increased in line with the increase in production capacity in salmon and shrimp. As a result, the division delivered strong Adjusted EBITDA growth to GBP10.1m (2018: GBP7.9m) with Adjusted EBITDA margin rising to 25% (2018: 22%).
Animal Health
Revenue of GBP17.7m up 10% (2018: GBP16.2m). Growth was driven by an increase in sales of Salmosan, the Company's current sea lice treatment. This reflects the challenge of high sea lice levels, particularly in Chile. The Company continued to generate a contribution from commercial scale field trials of its next generation sea lice treatment (BMK08), although at a lower level than the prior year, as we approach commercial launch and the programme of trials in our main market reaches conclusion. Revenues from veterinary and diagnostics services also grew during the year.
Total R&D investment in the division was GBP11.2m (2018: GBP12.2m), of which GBP5.7m was expensed (2018: GBP5.6m). During the year the Company began a programme to reduce overall R&D spend while continuing to progress the main pipeline opportunities. This involved a streamlining of external R&D spend and a review of in-house trials facilities. The impact from this effort will come through from 2020 onwards.
Adjusted EBITDA loss narrowed for the division to GBP10.2m (2018: loss of GBP11.0m).
Knowledge Services
All operations of the division are included within discontinued operations. Revenue in this division in 2019 was GBP15.9m (2018: GBP15.8m) with associated Adjusted EBITDA of GBP1.3m (2018: GBP0.2m). Revenue was flat with a particularly strong performance in veterinary training offset by reduced sales in other businesses. Despite being broadly complementary to Benchmark's core activities, the Knowledge Services division is not integral to the Group's long-term strategy. Therefore, the disposal of the component businesses is part of the programme of structural efficiencies. The Company is in discussions with a number of interested parties and further announcements will be made in due course.
Exceptional items
Items that are material because of their nature whose significance is sufficient to warrant separate disclosure and identification within the consolidated financial statements are referred to as exceptional items. The separate reporting of exceptional items helps to provide an understanding of the Group's underlying performance. Exceptional expenses related to continuing operations of GBP0.6m (2018: GBP1.2m) derive from the changes in Group management. Exceptional expenses relating to discontinued operations of GBP0.7m (2018: GBPnil) include costs of closure of operations in the Knowledge Services division.
Depreciation, amortisation and impairments
Depreciation and impairments related to continuing operations of GBP8.5m (2018: GBP4.9m) with the increase principally arising from new production facilities coming onstream.
Amortisation and impairments related to continuing operations of GBP64.3m (2018: GBP16.8m) with the increase being due to impairments in the carrying value of goodwill related to the INVE business driven by the change in market outlook.
Net finance costs
During the year the Company completed a new senior secured floating rate bond issue of NOK 850m (USD 95.0m equivalent). The bond which matures in June 2023, will be listed on the Oslo market and has a coupon equivalent to the three months Norwegian Interbank Offered Rate + 5.25% p.a. with quarterly interest payments. This new bond issue was applied to refinance Benchmark's previous USD 90m revolving credit facility. In addition, a USD 15.0m revolving credit facility was provided by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%). The revolving credit facility incurs interest in the range of 3.0 to 3.5% over London Interbank Offered Rate. The Group's other ring-fenced facilities remained in place including facilities totalling NOK 291m related to the funding of the new salmon egg production facility in Norway. Interest on these other debt facilities ranges between 2.65% above Norwegian base rates and 5%.
The Group incurred net finance costs from continuing operations of GBP12.1m during the year (2018: GBP4.6m). Included within this was interest charged on the Group's interest-bearing debt facilities of GBP6.0m (2018: GBP2.4m) reflecting a higher level of net debt during the year and the higher coupon post refinancing. Further, a foreign exchange loss of GBP4.6m arose due to the movement in exchange rates and there was a charge of GBP1.7m (2018: GBPnil) relating to the fair value change in the cross currency hedge taken out during the year.
Statutory loss before tax
The loss before tax from continuing operations for the year at GBP73.3m is higher than the prior year (2018: loss of GBP8.4m) due to the impact of the reduced trading result; higher depreciation, amortisation, and in particular impairment charges; and the increase in finance costs and exceptional costs; all as outlined above.
Taxation
There was a tax credit related to continuing operations in the period of GBP13,000 (2018: credit of GBP8.9m), mainly due to overseas tax charges in the Genetics division of GBP1.5m and in the Advanced Nutrition division of GBP2.6m, offset by deferred tax credits on intangible assets mainly arising on consolidation from acquisitions (the 2018 credit principally related to a reduction in the corporation tax rate in Belgium from 34% to 25%), recognition of a deferred tax asset on losses expected to be recovered.
Loss for the year
The loss for the year from continuing operations was GBP73.3m (2018: profit of GBP0.5m) and from discontinued operations the loss was GBP9.8m (2018: loss of GBP4.9m).
Earnings per share
Basic loss and diluted loss per share were both -15.03p (2018: loss per share -0.94p). The movement year on year is due to the reduced result for the year as noted above.
Dividends
No dividends have been paid or proposed in the year (2018: GBPnil) and the Board is not recommending a final dividend in respect of the year ended 30 September 2019.
Biological assets
A feature of the Group's net assets is its investment in biological assets, which under IAS 41 are stated at fair value. At 30 September 2019, the carrying value of biological assets was GBP28.5m (2018: GBP20.4m). The movement in the overall carrying value of biological assets is due principally to the increase in sales of and future orders for the Company's salmon eggs as well as expansion of own production.
Intangibles
Capitalised R&D increased by GBP0.5m to GBP7.7m (2018: GBP7.2m). R&D costs related to products that are close to commercial launch have to be capitalised when they meet the requirements set out under IFRS. Increased activities related to trials of and progress with the marketing authorisation application for BMK08 pushed capitalised development costs higher, together with the first time capitalisation of the new shrimp genetics. As Benchmark goes through a period of an increasing number of new products approaching launch this capitalisation will be an ongoing feature in the mid-term.
The dissolution of the genetics joint venture in Chile, and the consequent transfer of assets to Benchmark to part satisfy return of the original investment, led to an intangible addition representing the IP inherent within the breeding programme in Chile.
The impairment of intangible assets during the year of GBP47.6m principally relates to impairment of the goodwill from the acquisition of INVE where the change in market outlook has led to a reduction in value of the discounted cash flows for the Advanced Nutrition division.
Capital expenditure
Tangible fixed asset additions of GBP12.5m (2018: GBP25.1m) includes GBP1.0m cash investment in the final phase of the construction of the new salmon egg production facility in Norway, GBP4.1m initial investment in the new salmon egg production facility in Chile (transferred on dissolution of the previous JV) and GBP2.2m on improvements to salmon slaughter facilities in Iceland that are a vital part of the egg production process.
Cash flow
Net cash flow from operations was an outflow of GBP9.2m (2018: outflow of GBP3.7m) principally due to working capital increases: in Advanced Nutrition from purchase commitments with key live feed suppliers and in general the phasing of sales towards year end in general. In addition, the build of biological assets at new genetics production facilities resulted in an increased outflow in working capital of GBP8.6m (2018: outflow of GBP4.1m).
Total outflows to capex of GBP15.8m (2018: GBP32.7m) were substantially reduced because investment in the new salmon egg facility concluded at the beginning of the year.
Other cashflow items included the payment of the deferred consideration of GBP7.0m for the investment in the joint venture with AquaChile which was completed in 2018 and the initial consideration received on the subsequent dissolution of that joint venture in 2019 of GBP5.9m. The balance of the consideration for the dissolution of the joint venture of GBP6.9m was received post year end.
As a result of the above free cash flow was an outflow of GBP23.9m (2018: outflow of GBP36.2m). Net proceeds from increased borrowings of GBP21.4m were used to fund this outflow.
Cash at the period end stood at GBP16.1m (2018: GBP24.1m).
Liquidity and net debt
The Group's finance function is responsible for sourcing and structuring borrowing requirements.
As detailed under net finance costs above, during the year the Company completed a refinancing including a new senior secured floating rate bond issue of NOK 850m (USD95.0m equivalent) and a USD 15.0m revolving credit facility. The Group's other ring-fenced facilities remained in place including facilities totalling NOK 291m related to the funding of the new salmon egg production facility in Norway.
The Group had GBP103.2m in bank borrowings at the end of the year (2018: GBP79.7m). Reported debt includes GBP27.1m in relation to the funding of the Group's new salmon egg production facility in Norway. This is ring-fenced debt within SalmoBreed Salten without recourse to the rest of the Group. At the year end a maximum of GBP12.2m was available on the Group's super senior revolving credit facility, of this GBPnil had been drawn. Net debt increased to GBP87.1m during the year (2018: GBP55.7m) as investment in working capital expanded and available long-term capital was invested in R&D and production capacity.
There is an information undertaking within the terms of the NOK bond that requires the Company to publish quarterly financial statements within 60 days of the quarter end. The Company did not satisfy this requirement for the quarter to 30 September 2019 because the year end audit was not sufficiently complete for the publication of what would have effectively been deemed a Preliminary Announcement by reference to the UK Listing Rules. The NOK bond terms include permission for the Company to publish the quarterly financials within 20 business days of the end of the initial 60 day period. The Company satisfied the requirements of the NOK bond terms by announcing its quarterly financials simultaneously with the announcement of its preliminary results for the year ended 30 September 2019 on 20 December 2019.
The facilities combined with the year end cash balance of GBP16.1m means the Group had total liquidity of GBP28.2m. This, in conjunction with the expected proceeds from the disposal of non-core businesses and the reduction in cash outflows resulting from closing certain non-core activities is expected by the Directors to provide the Group with sufficient liquidity to fund continuing growth and provide adequate headroom.
Consolidated Income Statement
for the year ended 30 September 2019
Notes 2019 2018
Restated
GBP000 GBP000
------------------------------------------------- ------ --------- ---------
Continuing operations
Revenue 127,343 131,643
Cost of sales (61,348) (63,150)
------------------------------------------------- ------
Gross profit 65,995 68,493
Research and development costs (12,830) (12,040)
Other operating costs (40,700) (37,012)
Share of profit of equity-accounted investees,
net of tax (414) (362)
------------------------------------------------- ------ --------- ---------
Adjusted EBITDA(2) 12,051 19,079
Exceptional - restructuring/acquisition related
items 4 (581) (1,239)
------------------------------------------------- ------ --------- ---------
EBITDA(1) 11,470 17,840
Depreciation and impairment (8,466) (4,869)
Amortisation and impairment (64,254) (16,802)
------------------------------------------------- ------ --------- ---------
Operating loss (61,250) (3,831)
Finance cost 3 (12,422) (4,927)
Finance income 3 368 332
------------------------------------------------- ------ --------- ---------
Loss before taxation (73,304) (8,426)
Tax on loss 13 8,906
------------------------------------------------- ------ --------- ---------
(Loss)/profit from continuing operations (73,291) 480
------------------------------------------------- ------ --------- ---------
Discontinued operations
Loss from discontinued operations, net of tax 5 (9,789) (4,869)
------------------------------------------------- ------ --------- ---------
(83,080) (4,389)
------------------------------------------------- ------ --------- ---------
Loss for the year attributable to:
- Owners of the parent (83,857) (5,009)
- Non-controlling interest 777 620
------------------------------------------------- ------ ---------
(83,080) (4,389)
------------------------------------------------- ------ --------- ---------
Earnings per share
Basic loss per share (pence) 6 (15.03) (0.94)
Diluted loss per share (pence) 6 (15.03) (0.94)
Earnings per share - continuing operations
Basic loss per share (pence) 6 (13.28) (0.03)
Diluted loss per share (pence) 6 (13.28) (0.03)
GBP000 GBP000
------------------------------------------------- ------ --------- ---------
Adjusted EBITDA from continuing operations 12,051 19,079
Adjusted EBITDA from discontinued operations 1,674 (2,061)
------------------------------------------------- ------ --------- ---------
Total Adjusted EBITDA 13,725 17,018
------------------------------------------------- ------ --------- ---------
(1) EBITDA - Earnings before interest, tax, depreciation, amortisation and impairment
(2) Adjusted EBITDA - EBITDA before exceptional and acquisition related items
Consolidated Statement of Comprehensive Income
for the year ended 30 September 2019
2019 2018
GBP000 GBP000
-------------------------------------------------------- --------- --------
Loss for the year (83,080) (4,389)
Other comprehensive income
Items that are or may be reclassified subsequently
to profit or loss
Foreign exchange translation differences 13,919 7,624
Cash flow hedges - changes in fair value (3,549) -
Cash flow hedges - reclassified to profit or loss (17) -
Total comprehensive income for the period (72,727) 3,235
--------------------------------------------------------- --------- --------
Total comprehensive income for the period attributable
to:
- Owners of the parent (73,174) 2,546
- Non-controlling interest 447 689
---------------------------------------------------------
(72,727) 3,235
-------------------------------------------------------- --------- --------
Total comprehensive income for the period attributable
to owners of the parent:
- Continuing operations (63,188) 7,048
- Discontinued operations (9,986) (4,502)
---------------------------------------------------------
(73,174) 2,546
-------------------------------------------------------- --------- --------
Consolidated Balance Sheet
as at 30 September 2019
2019 2018
Notes GBP000 GBP000
------------------------------------------ ------ ---------- ----------
Assets
Property, plant and equipment 7 88,900 99,527
Intangible assets 8 275,744 325,386
Equity-accounted investees 3,453 17,457
Other investments 25 29
Biological and agricultural assets 10 12,469 8,502
Trade and other receivables - 4,145
Non-current assets 380,591 455,046
------------------------------------------ ------ ---------- ----------
Inventories 22,609 20,483
Biological and agricultural assets 16,024 11,892
Trade and other receivables 52,136 41,337
Cash and cash equivalents 16,051 24,090
------------------------------------------ ------ ---------- ----------
106,820 97,802
Assets held for sale 15,970 -
Current assets 122,790 97,802
------------------------------------------ ------ ---------- ----------
Total assets 503,381 552,848
------------------------------------------ ------ ---------- ----------
Liabilities
Trade and other payables (35,235) (45,680)
Loans and borrowings 11 (3,231) (898)
Corporation tax liability (2,703) (2,629)
Provisions (404) (70)
------------------------------------------ ------ ---------- ----------
(41,573) (49,277)
Liabilities directly associated (10,634) -
with the assets held for sale
Current liabilities (52,207) (49,277)
------------------------------------------ ------ ---------- ----------
Loans and borrowings (99,961) (78,868)
Other payables (2,004) (1,219)
Deferred tax (38,743) (41,637)
Non-current liabilities (140,708) (121,724)
------------------------------------------ ------ ---------- ----------
Total liabilities (192,915) (171,001)
------------------------------------------ ------ ---------- ----------
Net assets 310,466 381,847
------------------------------------------ ------ ---------- ----------
Issued capital and reserves attributable
to owners of the parent
Share capital 559 557
Additional paid-in capital 358,044 357,894
Capital redemption reserve 5 5
Retained earnings (110,916) (28,240)
Hedging Reserve (3,566) - Foreign exchange reserve 60,202 45,953 Equity attributable to owners of the parent 304,328 376,169 Non-controlling interest 6,138 5,678 ------------------------------------------ ------ Total equity and reserves 310,466 381,847 ------------------------------------------ ------ ---------- ----------
Consolidated Statement of Changes in Equity
for the year ended 30 September 2019
Total
attributable
Additional to equity
paid-in holders Non-
Share share Other Hedging Retained of controlling Total
capital capital reserves reserve earnings parent interest equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
As at 1
October 2017 522 339,431 38,403 - (24,742) 353,614 4,971 358,585
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Comprehensive
income
for the period
(Loss) for the
period - - - - (5,009) (5,009) 620 (4,389)
Other
comprehensive
income - - 7,555 - - 7,555 69 7,624
Total
comprehensive
income
for the
period - - 7,555 - (5,009) 2,546 689 3,235
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Contributions
by and
distributions
to owners
Share issue 35 18,463 - - - 18,498 - 18,498
Share based
payment - - - - 1,511 1,511 - 1,511
Total
contributions
by
and
distributions
to
owners 35 18,463 - - 1,511 20,009 - 20,009
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Changes in
ownership
Acquisition of
NCI without
a change in
control - - - - - - 18 18
Total changes
in ownership
interests - - - - - - 18 18
Total
transactions
with
owners of the
Company 35 18,463 - - 1,511 20,009 18 20,027
As at 30
September
2018 557 357,894 45,958 - (28,240) 376,169 5,678 381,847
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Comprehensive
income
for the period
(Loss) for the
period - - - - (83,857) (83,857) 777 (83,080)
Other
comprehensive
income - - 14,249 (3,566) - 10,683 (330) 10,353
Total
comprehensive
income
for the
period - - 14,249 (3,566) (83,857) (73,174) 447 (72,727)
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Contributions
by and
distributions
to owners
Share issue 2 150 - - - 152 - 152
Share based
payment - - - - 1,181 1,181 - 1,181
Total
contributions
by
and
distributions
to
owners 2 150 - - 1,181 1,333 - 1,333
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Changes in
ownership
Disposal of
subsidiary
with NCI - - - - - - 13 13
Total changes
in ownership
interests - - - - - - 13 13
Total
transactions
with
owners of the
Company 2 150 - - 1,181 1,333 13 1,346
As at 30
September
2019 559 358,044 60,207 (3,566) (110,916) 304,328 6,138 310,466
--------------- --------- ------------ ---------- ---------- ---------- -------------- ------------- ---------
Consolidated Statement of Cash Flows
for the year ended 30 September 2019
2019 2018
Notes GBP000 GBP000
------------------------------------------- ------- --------- ---------
Cash flows from operating activities
Loss for the year (83,080) (4,389)
Adjustments for:
Depreciation and impairment of property,
plant and equipment 17,227 6,841
Amortisation and impairment of intangible
fixed assets 66,087 18,002
Loss on sale of property, plant and
equipment (838) 8
Finance income (368) (332)
Finance costs 7,773 2,432
Other adjustments for non-cash items 68 (1,931)
Share of profit of equity-accounted
investees, net of tax 414 362
Foreign exchange losses 5,620 2,609
Share based payment expense 1,181 1,511
Tax credit 111 (9,270)
---------------------------------------------------- --------- ---------
14,195 15,843
Increase in trade and other receivables (12,516) (4,355)
Increase in inventories (2,273) (815)
Increase in biological and agricultural
assets (8,593) (4,102)
Increase/(decrease) in trade and
other payables 3,968 (4,026)
Increase/(decrease) in provisions 261 (388)
---------------------------------------------------- --------- ---------
(4,958) 2,157
Income taxes paid (4,253) (5,898)
---------------------------------------------------- --------- ---------
Net cash flows used in operating
activities (9,211) (3,741)
---------------------------------------------------- --------- ---------
Investing activities
Acquisition of subsidiaries, net
of cash acquired (7) -
Purchase of investments (7,020) (6,356)
Receipts from disposal of investments 5,942 -
Purchases of property, plant and
equipment (7,850) (25,072)
Purchase of intangibles (7,964) (7,581)
Proceeds from sale of fixed assets 1,131 233
Interest received 447 261
---------------------------------------------------- --------- ---------
Net cash flows used in investing
activities (15,321) (38,515)
---------------------------------------------------- --------- ---------
Financing activities
Proceeds of share issues 2 18,498
Proceeds from bank or other borrowings 92,578 41,206
Acquisition of NCI - (33)
Repayment of bank or other borrowings (71,224) (5,815)
Cash advances and loans made to other
parties - (4,076)
Interest and finance charges paid (5,366) (2,442)
Payments to finance lease creditors (5) (218)
---------------------------------------------------- --------- ---------
Net cash inflow from financing activities 15,985 47,120
---------------------------------------------------- --------- ---------
Net (decrease)/increase in cash and
cash equivalents (8,547) 4,864
Cash and cash equivalents at beginning
of year 24,090 18,779
Effect of movements in exchange rate 508 447 ---------------------------------------------------- --------- --------- Cash and cash equivalents at end of year 16,051 24,090 ---------------------------------------------------- --------- ---------
Notes
1. Basis of preparation
These audited results have been prepared on the basis of the accounting policies which are to be set out in Benchmark Holdings Plc's annual report and financial statements for the year ended 30 September 2019.
The consolidated financial statements of the Group for the year ended 30 September 2019 were prepared in accordance with International Financial Reporting Standards ("IFRSs") as adopted for use in the EU ("adopted IFRSs") and applicable law.
Whilst the financial information included in this preliminary statement has been prepared on the basis of the requirements of IFRSs in issue, as adopted by the European Union and effective at 30 September 2019, this statement does not itself contain sufficient information to comply with IFRS.
The financial information set out above does not constitute the company's statutory accounts for the years ended 30 September 2019 or 2018 but is derived from those accounts. Statutory accounts for 2018 have been delivered to the registrar of companies, and those for 2019 will be delivered in due course. The auditor has reported on those accounts. Their report for 2019 was (i) unqualified, (ii) contains a material uncertainty in respect of going concern to which the auditor drew attention by way of emphasis without modifying their report and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Their report for the accounts of 2018 was (i) unqualified, (ii) did not include a reference of any matters to which the auditor drew attention by way of emphasis without qualifying their report and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
The financial statements are prepared on the going concern basis.
As at 30 September 2019 the Group had net assets of GBP310.5m (2018: GBP381.8m), including cash of GBP16.1m (2018: GBP24.1m) as set out in the consolidated balance sheet. The Group made a loss for the year of GBP83.1m (2018: GBP4.4m). As at 30 September 2019 the Company had net assets of GBP304.2m (2018: GBP341.5m), including cash of GBP0.8m (2018: GBP2.3m. The Company made a loss for the year of GBP35.2m (2018: GBP8.6m).
The Group was refinanced during the year, and on 24 June 2019 a new four-year senior secured floating rate listed bond issue of NOK 850m was completed and a new three and a half year USD 15m revolving credit facility agreed. As at 20 December total borrowings from the Group's facilities were GBP102.3m and the most recent month end cash reserves at the end of November were GBP19.8m.
The Directors have prepared base and sensitised cash flow forecasts for the Group covering the period to September 2021, including forecast compliance with the covenants specified in the new borrowings. Significant elements of the Group continue to be in a growth and investment phase, including the final stages of obtaining Marketing Authority approval for its latest sea lice treatment and the growth and expansion of its genetics business into inland salmon egg production and disease resistant shrimp genetics while riding out the headwinds in the shrimp market. The Directors have taken the decision to divest from a number of smaller or non-core businesses in the Group to help fund this ongoing investment and a structural efficiencies programme is well underway to that end. The business forecasts therefore include key assumptions on the timing and value of these business disposals and asset realisations, as well as other trading uncertainties common in businesses engaged in the aquaculture and research and development industries. The trading uncertainties include the timing of the grant of full licences for the new sea lice treatment, the pace of recovery in global shrimp markets, achieving anticipated growth targets in core Advanced Nutrition and Genetics markets, the supply and pricing of key raw materials and potential distribution partner agreements. However good progress has been made with all of the disposals subject to the non-core divestment programme, with several reaching the non-binding offer stage and offers received reflecting a high level of interest.
The Directors have considered reasonably possible downside sensitivity scenarios, including mitigating actions within their control, should these occur around deferring and reducing non-essential capital and revenue expenditure and working capital management. These forecast cash flows, considering the ability and intention of the directors to implement mitigating actions should they be required, provide sufficient headroom in the forecast period. However, should the reasonably possible downside sensitivities from trading occur, alongside a significant delay, or a reduction in the expected disposal proceeds below the low end of the valuation range in some of the larger business disposals, then this could remove all available headroom. In this event, either further financing would have to be sought or additional structural efficiency initiatives be identified and pursued. In the eventuality that further financing is required, the Directors believe that relationships with funders and the expected returns available on the growth areas within the Group in which ongoing investment is being made are sufficiently strong and attractive for the Group to be able to secure adequate additional funding should it be required.
Based on their assessment, the Directors believe it remains appropriate to prepare the financial statements on a going concern basis. However, these circumstances represent a material uncertainty that may cast significant doubt on the Group's and Company's ability to continue as a going concern and therefore to continue realising their assets and discharging its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.
2 Segment information
Operating segments are reported in a manner consistent with the reports made to the chief operating decision maker. It is considered that the role of chief operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into reportable segments as follows:
-- Animal Health Division - provides veterinary services, environmental services diagnostics and animal health products to global aquaculture, and manufactures licenced veterinary vaccines and vaccine components;
-- Benchmark Genetics Division - harnesses industry leading salmon breeding technologies combined with state-of-the-art production facilities to provide a range of year-round high genetic merit ova;
-- Advanced Animal Nutrition Division - manufactures and provides technically advanced nutrition and health products to the global aquaculture industry.
In addition to the above, reported as "all other segments" is the Knowledge Services division, this was created on 1 October 2017 by a combination of Sustainability Science Division and Technical Publishing Division, the results of which were not significant on an individual basis. The division provides sustainable food production consultancy, technical consultancy and assurance services and promotes sustainable food production and ethics through online news and technical publications for the international agriculture and food processing sectors and through delivery of training courses to the industries.
In order to reconcile the segmental analysis to the Consolidated Income Statement, Corporate and Inter-segment sales are also shown. Corporate represents revenues earned from recharging certain central costs to the operating divisions, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external customers, with an appropriate discount being applied to encourage use of Group resources at a rate acceptable to local tax authorities. This policy was applied consistently throughout the current and prior period.
Year ended 30 September Advanced All
2019 Animal Animal other Inter-segment
Health Genetics Nutrition segments Corporate sales Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
---------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Revenue 17,742 39,696 76,776 15,881 6,534 (7,890) 148,739
Cost of sales (14,112) (14,376) (37,502) (8,059) (394) 1,515 (72,928)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Gross profit / (loss) 3,630 25,320 39,274 7,822 6,140 (6,375) 75,811
Research and development
costs (5,691) (3,986) (3,173) - - - (12,850)
Operating costs (8,136) (10,845) (20,695) (6,558) (8,963) 6,375 (48,822)
Share of profit of
equity-accounted
investees, net of tax - (414) - - - - (414)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Adjusted EBITDA (10,197) 10,075 15,406 1,264 (2,823) - 13,725
Exceptional -
restructuring/acquisition
related items - (58) - (745) (523) - (1,326)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
EBITDA (10,197) 10,017 15,406 519 (3,346) - 12,399
Depreciation and impairment (4,400) (2,807) (1,878) (8,025) (117) - (17,227)
Amortisation and impairment (216) (2,079) (61,959) (1,833) - - (66,087)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Operating profit / (loss) (14,813) 5,131 (48,431) (9,339) (3,463) - (70,915)
Finance cost (12,422)
Finance income 368
Loss before tax (82,969)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Year ended 30 September Advanced All
2018 Animal Animal other Inter-segment
Health Genetics Nutrition segments Corporate sales Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
---------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Revenue 16,153 35,755 85,746 15,786 5,277 (7,250) 151,467
Cost of sales (13,494) (14,822) (40,998) (9,811) (440) 2,118 (77,447)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Gross profit / (loss) 2,659 20,933 44,748 5,975 4,837 (5,132) 74,020
Research and development
costs (5,593) (3,611) (2,836) - - - (12,040)
Operating costs (8,058) (9,089) (20,285) (5,772) (6,632) 5,236 (44,600)
Share of profit of
equity-accounted
investees, net of tax - (362) - - - - (362)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Adjusted EBITDA (10,992) 7,871 21,627 203 (1,795) 104 17,018
Exceptional -
restructuring/acquisition
related items - (1,013) - - (226) - (1,239)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
EBITDA (10,992) 6,858 21,627 203 (2,021) 104 15,779
Depreciation (2,459) (1,330) (1,679) (1,242) (131) - (6,841)
Amortisation and impairment (108) (2,171) (14,523) (1,200) - - (18,002)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Operating profit / (loss) (13,559) 3,357 5,425 (2,239) (2,152) 104 (9,064)
Finance cost (4,927)
Finance income 332
Loss before tax (13,659)
----------------------------- --------- ---------- ----------- ---------- ----------- --------------- ---------
Reconciliation of segmental information to IFRS measures - Revenue and Loss before tax
Revenue
2019 2018
GBP000 GBP000
-------------------------------------------- --------- ---------
Total revenue per segmental information 148,739 151,467
Less: revenue from discontinued operations (21,396) (19,824)
--------------------------------------------- --------- ---------
Consolidated revenue 127,343 131,643
--------------------------------------------- --------- ---------
Loss before tax
2018
GBP000 GBP000
---------------------------------------------------- --------- ---------
Loss before tax per segmental
information (82,969) (13,659)
Less: loss before tax from discontinued operations 9,665 5,233
----------------------------------------------------- --------- ---------
Consolidated loss before tax (73,304) (8,426)
----------------------------------------------------- --------- ---------
3 Net finance costs
2019 2018
GBP000 GBP000
---------------------------------------------------- --------- --------
Interest received on bank deposits 366 301
Dividend income 2 31
----------------------------------------------------- --------- --------
Finance income 368 332
----------------------------------------------------- --------- --------
Finance leases (interest portion) (65) (5)
Foreign exchange losses on financing activities (1,594) (1,054)
Foreign exchange losses on operating activities (3,055) (1,441)
Cash flow hedges - reclassified from OCI 17 -
Cash flow hedges - ineffective portion of changes (1,696) -
in fair value
Interest expense on financial liabilities measured
at amortised cost (6,029) (2,427)
----------------------------------------------------- --------- --------
Finance costs (12,422) (4,927)
----------------------------------------------------- --------- --------
Net finance costs recognised in profit or loss (12,054) (4,595)
----------------------------------------------------- --------- --------
4 Exceptional items -restructuring/acquisition related items
Items that are material because of their nature, non-recurring or whose significance is sufficient to warrant separate disclosure and identification within the consolidated financial statements are referred to as exceptional items. The separate reporting of exceptional items helps to provide an understanding of the Group's underlying performance.
2019 2018
GBP000 GBP000
---------------------------- ------- -------
Acquisition related items (82) 1,239
Exceptional restructuring
costs 663 -
Total exceptional items 581 1,239
----------------------------- ------- -------
Acquisition related items are costs incurred in investigating and acquiring new businesses. During the year, the contingent consideration element of the provision for deferred consideration held for previous acquisitions has been recalculated considering up to date performance of those acquisitions and the projected performance for the final 3 months of the earn out period (which ends on 31 December 2019) against the relevant sales volumes and revenue targets. As a result, GBP86,000 (2018: GBP206,000) has been released in the year.
Exceptional expenses include: GBP214,000 of legal fees and GBP391,000 of staff costs relating to the board's decision to make significant changes to management team and bring in new management and GBP58,000 of other items.
5 Discontinued operations
In June 2019 the Group announced a programme of structural efficiencies which focused on the disposal and discontinuation of non-core activities. This programme primarily includes the businesses of Knowledge Services Division and the veterinary services business within Animal Health Division.
Consequently, these operations have been classified as discontinued and part of the disposal group is presented as held for sale. The disposal group includes assets and liabilities within the Knowledge Services and Animal Health segments. The comparative consolidated statement of profit or loss and OCI has been represented to show the discontinued operations separately from continuing operations.
The disposals, together with the cost reduction/cost containment plan and enhanced working capital management will allow the Company to reallocate resources to priority revenue generating strategic projects and to maintain adequate headroom. The timing and proceeds from these actions are fundamental to maintain sufficient liquidity to execute the Group's product development programme and to support its Continuing Operations.
Significant progress to sell the disposal group has been made and sales are expected to complete within the first half of the financial year 2020.
Impairment losses relating to the disposal group
Impairment losses of GBP7,533,000 for write downs of discontinued operations to the lower of carrying amount and its fair value less costs to sell have been included in the "Depreciation and impairment" and "Amortisation and impairment" headings within discontinued operations. The impairment losses have been applied to reduce the carrying amount of Intangible assets and property, plant and equipment.
Results from discontinued operations
2019 2018
GBP000 GBP000
----------------------------------------- --------- ---------
Revenue 21,396 19,824
Cost of sales (11,580) (14,297)
------------------------------------------
Gross profit 9,816 5,527
Research and development costs (20) -
Other operating costs (8,122) (7,588)
------------------------------------------ --------- ---------
Adjusted EBITDA 1,674 (2,061)
Exceptional - restructuring/acquisition
related items (745) -
----------------------------------------- --------- ---------
EBITDA 929 (2,061)
Depreciation and impairment (8,761) (1,972)
Amortisation and impairment (1,833) (1,200)
------------------------------------------ --------- ---------
Operating loss / Loss before taxation (9,665) (5,233)
Tax on loss (124) 364
------------------------------------------ --------- ---------
Loss from discontinued operations (9,789) (4,869)
------------------------------------------ --------- ---------
Results from discontinued operations by segment
Animal Knowledge Total Animal Knowledge Total
Health Services Discontinued Health Services Discontinued
2019 2019 2019 2018 2018 2018
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
----------------- -------- ---------- -------------- -------- ---------- --------------
Revenue 6,255 15,141 21,396 5,467 14,357 19,824
Adjusted EBITDA 288 1,386 1,674 (1,744) (317) (2,061)
Operating loss (447) (9,218) (9,665) (2,475) (2,758) (5,233)
------------------ -------- ---------- -------------- -------- ---------- --------------
6 Loss per share
Basic loss per share is calculated by dividing the profit or loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares in issue during the period.
2019 2018
Continuing Discontinuing Total Continuing Discontinuing Total
------------------------- ----------- -------------- --------- ----------- -------------- --------
Loss attributable to
equity holders of the
parent (GBP000) (74,068) (9,789) (83,857) (140) (4,869) (5,009)
Weighted average number
of shares in issue
(thousands) 557,851 531,651
Basic loss per share
(pence) (13.28) (1.75) (15.03) (0.03) (0.91) (0.94)
Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. This is done by calculating the number of shares that could have been acquired at fair value (determined as the average market price of the Company's shares since admission to AIM) based on the monetary value of the subscription rights attached to outstanding share options and warrants.
Therefore, the Company is required to adjust the loss per share calculation in relation to the share options that are in issue under the Company's share-based incentive schemes as follows:
2019 2018
Continuing Discontinuing Total Continuing Discontinuing Total
------------------------- ----------- -------------- --------- ----------- -------------- --------
Loss attributable to
equity holders of the
parent (GBP000) (74,068) (9,789) (83,857) (140) (4,869) (5,009)
Weighted average number
of shares in issue
(thousands) 557,851 531,651
Diluted loss per share
(pence) (13.28) (1.75) (15.03) (0.03) (0.91) (0.94)
A total of 2,962,168 potential ordinary shares have not been included within the calculation of statutory diluted loss per share for the year (2018: 3,724,453) as they are anti-dilutive. However, these potential ordinary shares could dilute earnings/loss per share in the future.
7 Property, plant and equipment
Assets
Freehold in the Long Term Office
Land course Leasehold Plant Equipment
and of Property and E commerce and
Buildings construction Improvements Machinery Infra-structure Fixtures Total
Group GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
--------------------- ----------- ------------- ------------- ----------- ---------------- ----------- --------
Cost
Balance at 1 October
2017 32,956 27,152 4,281 25,591 247 1,227 91,454
Additions 1,678 17,705 874 3,593 - 1,222 25,072
Reclassification (2,450) - (99) 2,610 - (61) -
Increase/(decrease)
through transfers
from
assets in the
course
of construction 71 (5,060) 3,534 1,455 - - -
Exchange differences 196 573 10 475 - 117 1,371
Disposals (23) (10) (63) (636) - (224) (956)
Balance at 30
September
2018 32,428 40,360 8,537 33,088 247 2,281 116,941
--------------------- ----------- ------------- ------------- ----------- ---------------- ----------- --------
Balance at 1 October
2018 32,428 40,360 8,537 33,088 247 2,281 116,941
Additions 6,760 1,234 135 3,523 - 804 12,456
Increase/(decrease)
through transfers
from
assets in the
course
of construction 37,083 (38,376) 2 1,282 - 9 -
Exchange differences (237) (1,768) 9 827 - 204 (965)
Reclassification to
assets held for
resale (200) - (2,096) (6,228) (247) (489) (9,260)
Disposals (461) (146) (19) (1,013) - (190) (1,829)
Disposals through
sale
of subsidiary - - (102) (67) - (9) (178)
Balance at 30
September
2019 75,373 1,304 6,466 31,412 - 2,610 117,165
--------------------- ----------- ------------- ------------- ----------- ---------------- ----------- --------
Accumulated
Depreciation
Balance at 1 October
2017 2,414 - 1,211 6,388 244 352 10,609
Depreciation charge
for the year 1,269 - 843 4,410 2 317 6,841
Reclassification - - (5) 25 - (20) -
Exchange differences 193 - 34 359 - 93 679
Disposals (21) - (94) (515) - (85) (715)
Balance at 30
September
2018 3,855 - 1,989 10,667 246 657 17,414
--------------------- ----------- ------------- ------------- ----------- ---------------- ----------- --------
Balance at 1 October
2018 3,855 - 1,989 10,667 246 657 17,414
Depreciation charge
for the year 2,372 - 972 4,726 1 486 8,557
Impairment charge
for
the year - 295 3,079 4,714 - 9 8,097 Reclassification to assets held for resale (61) - (1,083) (3,853) (247) (241) (5,485) Exchange differences 302 - 52 730 - 214 1,298 Disposals (425) - - (921) - (191) (1,537) Disposals through sale of subsidiary - - (24) (49) - (6) (79) Balance at 30 September 2019 6,043 295 4,985 16,014 - 928 28,265 --------------------- ----------- ------------- ------------- ----------- ---------------- ----------- -------- Net book value At 30 September 2019 69,330 1,009 1,481 15,398 - 1,682 88,900 --------------------- ----------- ------------- ------------- ----------- ---------------- ----------- -------- At 30 September 2018 28,573 40,360 6,548 22,421 1 1,624 99,527 --------------------- ----------- ------------- ------------- ----------- ---------------- ----------- -------- At 1 October 2017 30,542 27,152 3,070 19,203 3 875 80,845 --------------------- ----------- ------------- ------------- ----------- ---------------- ----------- --------
Following the decision to proceed with the structural efficiencies plan, the carrying value of Property, plant and equipment assets in the relevant businesses has been reviewed for recoverability. A resulting impairment charge of GBP8,097,000 has been made against the carrying value of the various assets.
8 Intangible assets
Patents
and Intellectual Customer Development
Websites Goodwill Trademarks Property Lists Contracts Licences Genetics costs Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
Cost or valuation
Balance at 1
October 2017 597 149,941 811 134,638 6,784 9,510 34,664 26,245 3,531 366,721
Additions -
on acquisition - 51 - - - - - - - 51
Additions -
externally
acquired 86 - 30 118 - - - - 139 373
Additions -
internally
developed - - - - - - - - 7,178 7,178
Disposals - (447) - - - - - - - (447)
Exchange
differences 2 3,171 6 3,679 149 20 1,018 (59) 57 8,043
Balance at 30
September 2018 685 152,716 847 138,435 6,933 9,530 35,682 26,186 10,905 381,919
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
Balance at 1
October 2018 685 152,716 847 138,435 6,933 9,530 35,682 26,186 10,905 381,919
Additions -
on acquisition - - - 319 - - - - - 319
Additions -
externally
acquired 118 - 62 1,799 - - 38 - - 2,017
Additions -
internally
developed - - - - - - - - 7,673 7,673
Disposals through
sale of
subsidiary - (84) - - - - - - - (84)
Reclassification
to assets held
for resale (689) (4,657) (465) (1,691) (1,484) (2,431) - - - (11,417)
Exchange
differences (2) 5,414 (2) 7,942 323 (284) 1,357 (1,327) 128 13,549
Balance at 30
September 2019 112 153,389 442 146,804 5,772 6,815 37,077 24,859 18,706 393,976
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
Accumulated
amortisation
and impairment
Balance at 1
October 2017 531 276 631 22,902 1,028 5,506 4,899 1,811 - 37,584
Amortisation
charge for the
period 21 - 158 12,631 403 1,399 2,161 782 - 17,555
Impairment - 447 - - - - - - - 447
Disposals - (447) - - - - - - - (447)
Exchange
differences - 1 11 1,037 17 35 294 (1) - 1,394
Balance at 30
September 2018 552 277 800 36,570 1,448 6,940 7,354 2,592 - 56,533
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
Balance at 1
October 2018 552 277 800 36,570 1,448 6,940 7,354 2,592 - 56,533
Amortisation
charge for the
period 40 - (235) 13,884 608 1,389 1,874 686 - 18,246
Impairment - 45,346 - 2,209 - - - - - 47,555
Disposals - - - - - - - - - -
Reclassification
to assets held
for resale (584) (816) (445) (645) (1,264) (2,298) - - - (6,052)
Exchange
differences - - (28) 2,562 42 (196) (305) (125) - 1,950
Balance at 30
September 2019 8 44,807 92 54,580 834 5,835 8,923 3,153 - 118,232
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
Net book value
At 30 September
2019 104 108,582 350 92,224 4,938 980 28,154 21,706 18,706 275,744
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
At 30 September
2018 133 152,439 47 101,865 5,485 2,590 28,328 23,594 10,905 325,386
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
At 1 October
2017 66 149,665 180 111,736 5,756 4,004 29,765 24,434 3,531 329,137
------------------- --------- --------- ----------- ------------- --------- ---------- --------- --------- ------------ ---------
9 Impairment testing of goodwill and other intangible assets
Goodwill acquired in a business combination is allocated, at acquisition, to the cash generating units (CGUs) that are expected to benefit from the business combination. The Group tests goodwill annually for impairment, or more frequently if there are indications that goodwill might be impaired.
Goodwill arises across all of the Group's operating segments, and is allocated specifically against the following CGUs:
Animal Advanced Knowledge
Health Genetics Animal Nutrition Services Total
2019 2019 2019 2019 2019
GBP000 GBP000 GBP000 GBP000 GBP000
---------------------------------- -------- --------- ------------------ ---------- --------
Benchmark Vaccines Limited 432 - - - 432
Bencmark Genetics AS (previously
Salmobreed AS) - 7,065 - - 7,065
Stofnfiskur HF - 13,146 - - 13,146
Akvaforsk Genetic Center - 8,691 - - 8,691
INVE Aquaculture Group - - 79,248 - 79,248
-------- --------- ------------------ ---------- --------
432 28,902 79,248 - 108,582
---------------------------------- -------- --------- ------------------ ---------- --------
*Includes goodwill arising from the joint acquisition of Akvaforsk Genetics Center AS (which was transferred into Benchmark Genetics Norway) in the year and Benchmark Genetics USA (formerly Akvaforsk Genetics Center Inc.)
Animal Advanced Knowledge Total
Health Genetics Animal Nutrition Services
2018 2018 2018 2018 2018
GBP000 GBP000 GBP000 GBP000 GBP000
-------------------------------------- -------- --------- ------------------ ---------- --------
FVG Limited 288 - - - 288
Benchmark Vaccines Limited 432 - - - 432
Atlantic Veterinary Services Limited 167 - - - 167
Salmobreed AS - 7,435 - - 7,435
Stofnfiskur HF - 13,874 - - 13,874
Akvaforsk Genetic Center* - 9,194 - - 9,194
INVE Aquaculture Group - - 117,117 - 117,117
FAI do Brasil Criacao Animal Ltda - - - 96 96
FAI Aquaculture Limited - - - 450 450
5M Enterprises Limited - - - 379 379
Improve International Limited - - - 2,995 2,995
Improve International GmbH - - - 12 12
-------------------------------------- -------- --------- ------------------ ---------- --------
887 30,503 117,117 3,932 152,439
-------------------------------------- -------- --------- ------------------ ---------- --------
*Includes goodwill arising from the joint acquisition of Akvaforsk Genetics Center AS and Akvaforsk Genetics Center Inc
The recoverable amounts of the above CGUs, with the exception of the Knowledge Services, the operations of which are discontinued, have been determined from value in use calculations. These calculations used board approved cash flow projections from five-year business plans based on actual operating results and current forecasts. These forecasts were then extrapolated into perpetuity taking account of specific terminal growth rates for future cash flows, using individual business operating margins based on past experience and future expectations in light of anticipated economic and market conditions. The pre-tax cashflows that these projections produced were discounted at pre-tax discount rates based on the Group's beta adjusted cost of capital reflecting management's assessment of specific risks related to each cash generating unit. Specific assumptions used are as follows.
Animal Health
The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 13.1% (2018: 12.4%). An assumed CAGR of revenue of 49% (2018: 77%) in the five-year plan (2018: three-year plan) reflects the importance of the launch and commercialisation of the division's new sea lice treatment in the forecast period. A long-term growth rate of 2.5% (2018: 2.5%) has been used to extrapolate the terminal year cashflow into perpetuity.
The valuation of the Animal Health cash generating unit indicates sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment in related goodwill. However, should the division's new sea lice treatment not be successfully launched and commercialised, then impairment of the goodwill and other intangible assets could be possible.
Genetics
The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 12.1% (2018: 11.2%). CAGR of revenue of 15% (2018: 18%) is implied by the five-year plan (2018: three-year plan), and a long-term growth rate of 2.5% (2018: 2.5%) has been used to extrapolate the terminal year cashflow into perpetuity.
Sensitivity testing of the recoverable amount to reasonably possible changes in key assumptions has been performed. All other assumptions being unchanged, an increase in the pre-tax discount rate to 15.2% would reduce the headroom on the Genetics CGU to nil. Should the discount rate increase further than this, then an impairment of the goodwill would be likely.
Advanced Animal Nutrition
The continued aggressive shrimp market conditions being experienced during the year and the expectation of a slower longer-term recovery in that market led to a reduction in the recoverable value of the CGU. The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 11.5% (2018: 11.2%). CAGR of revenue of 12% (2018: 9%) is implied by the five-year plan, with the rate reflecting a particularly low year in FY19 and the recovery back to previous year's levels as well as growth from new products. Long term growth rate of 3.5% (2018: 4.0%) has been used to extrapolate the terminal year cashflow into perpetuity.
Following this review, the value in use calculation for the CGU showed GBP242m and a resulting impairment charge of GBP44.8m was made to the carrying value of the goodwill.
The value in use assessment is sensitive to changes in the key assumptions used. Sensitivity analysis was performed and a reasonably likely downside scenario reflecting a slower recovery of the shrimp market and a reduced growth rate in the five-year plan for new products. This reasonably likely downside scenario includes a 5% reduction in FY20 revenue and CAGR of revenue of 10% used in FY20 to FY24. This would likely cause further impairment of GBP13.2m.
Knowledge Services
Following the decision to pursue the Structural Efficiencies programme, the Knowledge Services CGU is discontinuing. The goodwill for 5M Enterprises Limited, Improve International Limited, Improve International GmbH have been transferred into Assets Held for Sale. The goodwill for FAI do Brasil Criacao Animal Ltda and FAI Aquaculture Limited no longer has any value and has been fully impaired.
10 Biological assets
2019 2018
Group GBP000 GBP000
---------------------------------- --------- --------
Organic sheep 58 123
Organic beef 43 150
Organic hens 23 26
Frozen Milt 477 484
Broodstock, eggs and fingerlings 27,892 19,611
---------------------------------- --------- --------
Total biological assets 28,493 20,394
---------------------------------- --------- --------
Less: non current broodstock (12,469) (8,502)
---------------------------------- --------- --------
Total current biological assets 16,024 11,892
---------------------------------- --------- --------
Livestock
The Group operates a commercial and research farming and technology transfer business, and at 30 September 2019 held 484 (2018: 2,192) head of sheep, 108 (2018: 299) head of cattle, and 10,256 (2018: 11,088) hens. In addition, livestock valued at GBP241,000 and comprising 1,366 head of sheep and 197 head of cattle have been reclassified as Assets held for sale. The Group had farming sales of GBP281,000 in the year ended 30 September 2019 (2018: GBP443,000), of which GBP238,000(2018: GBP349,000) relate to discontinued activities.
The Group is exposed to financial risks arising from changes in the market value of farm animals. The Group does not anticipate that prices will decline significantly in the foreseeable future and, therefore, has not entered into derivative or other contracts to manage the risk of a decline in livestock price. The Group reviews its outlook for livestock prices regularly in considering the need for active financial risk management.
Frozen Milt
Where we have identified individual salmon carrying particular traits or disease resistance, semen (milt) can be extracted and deep frozen using cryopreservation techniques (the process of freezing biological material at extreme temperatures in liquid nitrogen) . The calculation of the fair value of milt is based on production and freezing costs and, where appropriate, an uplift to recognise the additional selling price that can be achieved from eggs fertilised by premium quality milt. The estimated fair value of Frozen Milt at 30 September 2019 was GBP477,000 (2018: GBP484,000). The decrease in value of GBP7,000 relates to net usage during the year.
Broodstock, eggs and fingerlings
Lumpfish Tilapia
Salmon Salmon Salmon eggs and
Broodstock eggs fingerlings and fingerlings Shrimp Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
------------------------------------- ------------ --------- ------------- ----------------- -------- ---------
Biological assets 1 October 2018 11,724 5,772 265 1,585 265 19,611
Increase due to production /
purchase 25,463 721 399 4,050 43 30,676
Due to physical changes (20,165) 21,334 - - (53) 1,116
Foreign exchange movements (521) (331) (26) (58) (4) (940)
Reduction due to sales / discarding
of stock - (20,110) (355) (4,357) (119) (24,941)
Fair value adjustments 1,416 667 - 287 - 2,370
------------------------------------- ------------ --------- ------------- ----------------- -------- ---------
Biological assets 30 September
2019 17,917 8,053 283 1,507 132 27,892
------------------------------------- ------------ --------- ------------- ----------------- -------- ---------
Broodstock, eggs and fingerlings
- non current 12,469 - - - - 12,469
Broodstock, eggs and fingerlings
- current 5,448 8,053 283 1,507 132 15,423
------------------------------------- ------------ --------- ------------- ----------------- --------
17,917 8,053 283 1,507 132 27,892
------------------------------------- ------------ --------- ------------- ----------------- -------- ---------
Assumptions used for determining fair value of broodstock, eggs and fingerlings
IAS 41 requires that biological assets are accounted for at the estimated fair value net of selling and harvesting costs. Fair value is measured in accordance with IFRS 13 and is categorised into level 3 in the fair value hierarchy as the inputs include unobservable inputs in the valuation of broodstock, eggs and fingerlings for which there are no published market data available.
The calculation of the estimated fair value of salmon broodstock is primarily based upon its main harvest output being salmon eggs, which are priced upon our current seasonally adjusted selling prices for salmon eggs. These prices are reduced for harvesting costs, freight costs, incubation costs and market capacity to arrive at the net value of broodstock. The valuation also reflects the internally generated data to arrive at the biomass. This includes the weight of the broodstock, the yield that each kilogram of fish will produce and mortality rates. The fish take four years to reach maturity, and the age and biomass of the fish is taken into account in the fair value.
The calculation of the fair value of the salmon eggs is based upon the current seasonally adjusted selling prices for salmon eggs less transport and incubation costs and taking account of the market capacity. The valuation also takes account of the mortality rates of the eggs and expected life as sourced from internally generated data.
The calculation of the fair value of the salmon and lumpfish fingerlings is valued on current selling prices less transport costs. Internally generated data is used to incorporate mortality rates and the weight of the fish.
The lumpfish eggs are valued at cost. Internally generated data is used to calculate mortality rates.
The valuation models by their nature are based upon uncertain assumptions on sales prices, market capacity, weight, mortality rates, yields and assessment of the discounts to reflect the stages of maturity. The Group has a degree of expertise in these assumptions but these assumptions are subject to change. Relatively small changes in assumptions would have a significant impact on the valuation. A 1% increase/decrease in assumed selling price would increase/decrease the fair value of biological assets by GBP268,000. A 10% increase/decrease in the biomass of salmon broodstock and the quantity of salmon eggs valued would increase/decrease the fair value of those biological assets by GBP1,792,000 and GBP805,000 respectively.
Total quantities held at 30 September were:
2019 2018
---------------------------------- ----------- -----------
Salmon broodstock and fingerlings 805 tonnes 612 tonnes
Lumpfish fingerlings 3.2m 3.4m
units units
Salmon eggs 66.3m 51.0m
units units
---------------------------------- ----------- -----------
11 Loans and borrowings
2019 2018
GBP000 GBP000
---------------------------- -------- -------
Non-current
2023 850m NOK Loan notes 75,864 -
Bank borrowings 23,576 78,808
Other loans 60 60
Finance lease creditor 461 -
---------------------------- -------- -------
99,961 78,868
---------------------------- -------- -------
Current
Bank borrowings 3,102 894
Finance lease creditor 129 4
---------------------------- -------- -------
3,231 898
---------------------------- -------- -------
Total loans and borrowings 103,192 79,766
---------------------------- -------- -------
The fair value of loans and borrowings is not materially different to the carrying value and has not been separately disclosed.
On 30 December 2015, the Group entered into facilities consisting of a five-year revolving credit facility (expiring on 11 December 2020) of up to USD 70m secured on the assets of the parent company, UK subsidiary companies and certain overseas subsidiary companies. On 7 January 2019, the accordion facility within the Group's existing bank facility was activated raising the total facility from USD 70m to USD 90m. Liabilities under this facility were settled on 24 June 2019.
On 21 June 2019, the Group successfully completed a new senior secured floating rate listed bond issue of NOK 850m. The bond which matures in June 2023, has a coupon of three months NIBOR + 5.25% p.a. with quarterly interest payments, and will be listed on the Oslo Stock Exchange. The bond issue refinanced Benchmark's previous USD 90m credit facility. DNB Markets acted as Sole Bookrunner for the bond issue.
A USD 15m RCF has been provided by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%). This was undrawn at 30 September 2019.
SalmoBreed Salten AS had the following loans (which are ringfenced debt without recourse to the remainder of the Group) at 30 September 2019:
-- NOK 208.8m term loan provided by Nordea Bank Norge Abp. The loan is a five-year term loan ending November 2023 at an interest rate of 2.65% above 3-month NIBOR
-- NOK 20.0m working capital facility provided by Nordea Bank Norge Abp (of which NOK 15.0m had been drawn at 30 September 2019)
-- NOK 53.9m term loan provided by Innovasjon Norge. The loan is a twelve-and-a-half-year term loan ending March 2031 at an interest rate of 4.2% above Norges Bank base rate
NOK 19.75m loan provided by Salten Aqua ASA (the minority shareholder). The loan attracts interest at 2.5% above 3-month NIBOR and is repayable in a minimum of 5 years, but not before the Nordea
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
FR GUBDDRDDBGCG
(END) Dow Jones Newswires
December 20, 2019 02:00 ET (07:00 GMT)
1 Year Benchmark Chart |
1 Month Benchmark Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
